Tonix Pharmaceuticals

Tonix Pharmaceuticals(TNXP)

BERKELEY HEIGHTS, NJ
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: CNS Disorders

Tonix Pharmaceuticals is a life sciences company focused on CNS Disorders.

Neurology
Funding Stage
PUBLIC
Employees
5000+
Open Jobs
22

Products & Portfolio (1)

TONMYA
cyclobenzaprine hydrochloride
Launch
SUBLINGUAL · TABLET
2025
0

Pipeline & Clinical Trials

Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor
Pain, Face
Phase 1
Clinical Trials (1)
NCT06955650First-in-man Imaging of a New PET Radiotracer for Oxytocin Receptors
Phase 1
Phase 1
Clinical Trials (1)
NCT05216510Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
Phase 1
Treatment A
Healthy Adults
Phase 1
Clinical Trials (1)
NCT03168022Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.
Phase 1
TNX-102 SL Tablets at 2.8 mg
Healthy Adults
Phase 1
Clinical Trials (1)
NCT01889173Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults
Phase 1
TNX-201 35 mg
Healthy
Phase 1
Clinical Trials (1)
NCT02290379Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers
Phase 1
Treatment A
Healthy
Phase 1
Clinical Trials (1)
NCT01490788A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.
Phase 1
SL TNX-102 2.4 mg at pH 3.5
Healthy Adults
Phase 1
Clinical Trials (1)
NCT01634412Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults
Phase 1
TNX-102 SL 5.6 mg
Healthy Subjects
Phase 1
Clinical Trials (1)
NCT03443960Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules
Phase 1
Intranasal Oxytocin
Vasopressin Deficiency
Phase 1
Clinical Trials (1)
NCT04789148Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Phase 1
TNX-102 SL Tablet
Pharmakokinetic
Phase 1
Clinical Trials (1)
NCT07413367A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
Phase 1
Phase 1
Clinical Trials (1)
NCT04164719Dose-Proportionality and Food Effect Study of TNX-102 SL
Phase 1
SL TNX-102 at 2.4 mg
Healthy Adults
Phase 1
Clinical Trials (1)
NCT01689259Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults
Phase 1
Phase 2
Clinical Trials (1)
NCT05679908A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
Phase 2
TNX-601 ER
Depression
Phase 2
Clinical Trials (1)
NCT05686408Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
Phase 2
Cyclobenzaprine HCl
Acute Stress Reaction
Phase 2
Clinical Trials (1)
NCT06636786Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)
Phase 2
Phase 2
Clinical Trials (1)
NCT04996056An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects
Phase 2
TNX-1300
Cocaine Use
Phase 2
Clinical Trials (1)
NCT06045793Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
Phase 2
TNX-102 SL
PTSD
Phase 2
Clinical Trials (1)
NCT02421679Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
Phase 2
Phase 2
Clinical Trials (1)
NCT07204080(TNX-1500) in Kidney Transplant Recipients
Phase 2
TNX-102 SL
PTSD
Phase 2
Clinical Trials (1)
NCT02277704Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
Phase 2
TNX-102 SL
PTSD
Phase 2
Clinical Trials (1)
NCT05372887Safety and Efficacy Study of TNX-102 SL in Participants With PTSD
Phase 2
Phase 2
Clinical Trials (1)
NCT02423408Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
Phase 2
Phase 2
Clinical Trials (1)
NCT05472090A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
Phase 2
TNX-102 SL 2.8mg
Primary Fibromyalgia
Phase 2/3
Clinical Trials (1)
NCT01903265BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)
Phase 2/3
TNX-102 SL Tablet, 2.8mg
Fibromyalgia
Phase 3
Clinical Trials (1)
NCT02436096A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
Phase 3
TNX-102 SL
Fibromyalgia
Phase 3
Clinical Trials (1)
NCT04172831A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Phase 3
TNX-102 SL
Fibromyalgia
Phase 3
Clinical Trials (1)
NCT04508621A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
Phase 3
TNX-102 SL Tablet 2.8 mg
Primary Fibromyalgia
Phase 3
Clinical Trials (1)
NCT02589275A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Phase 3
TNX-102 SL
PTSD
Phase 3
Clinical Trials (1)
NCT03062540Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
Phase 3
TNX-102 SL Tablet, 5.6 mg
Fibromyalgia
Phase 3
Clinical Trials (1)
NCT05273749A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
Phase 3
TNX-102 SL 5.6 mg
PTSD
Phase 3
Clinical Trials (1)
NCT03508700A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Phase 3
TNX-102 SL Tablet, 2.8 mg
Fibromyalgia
Phase 3
Clinical Trials (1)
NCT02829814Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
Phase 3
TNX-102 SL
PTSD
Phase 3
Clinical Trials (1)
NCT03841773A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
Phase 3
TNX-102 SL
PTSD
Phase 3
Clinical Trials (1)
NCT0311057512-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
Phase 3
Phase 3
Clinical Trials (1)
NCT0201523412-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
Phase 3

Open Jobs (22)

Director, Commercial Operations and Analytics

Berkeley Heights, NJ
Commercial
12h ago

Senior Director, Market Access and Patient Services

Berkeley Heights, NJ
Commercial
4d ago

Director, Regulatory Affairs - Infectious Disease

Berkeley Heights, NJ
Clinical
6d ago

Medical Science Liaison (MSL) - New England

Boston, MA
Commercial
1w ago

Medical Science Liaison (MSL) - Heartland

Saint Louis, MO
Commercial
1w ago

Scientist I – Bioanalytical & Advanced Assay Development

Frederick, MD
Research & Development
1w ago

Manager, Trade & Market Access

Berkeley Heights, NJ
Commercial
1w ago
From $90K/yr

Scientist II, Animal Model Development

Frederick, MD
Research & Development
1w ago
From $70K/yr

Director, Clinical & Nonclinical Quality Assurance

Research & Development
3w ago
From $150K/yr

Thought Leader Liaison (TLL), East

Charlotte, NC
Commercial
3w ago
From $130K/yr

VP, Clinical Development - Infectious Disease

Clinical
3w ago
From $250K/yr

Thought Leader Liaison (TLL), West

Los Angeles, CA
Commercial
3w ago
From $130K/yr

Senior Specialist, QC

North Dartmouth, MA
Quality Assurance
3w ago
From $70K/yr

Senior Director and Head of DMPK & Bioanalytical

Frederick, MD
Research & Development
3w ago

Associate, Accounts Payable

Dublin, Ireland
Finance
3w ago

Manager, Field Enablement and Operations

Berkley Heights, NJ
Commercial
1mo ago
From $90K/yr

Associate Director, Supply Chain

Dublin, Ireland
Supply Chain
1mo ago

Senior Specialist, Regulatory Operations

Frederick, MD
Clinical
2mo ago
From $70K/yr

Vice President of Sales

Berkeley Heights, NJ
Commercial
2mo ago
From $250K/yr

Senior Scientist I, Mass Spectrometry

Frederick, MD
Research & Development
2mo ago
From $100K/yr

Associate Director, Brand Marketing

Berkeley Heights, NJ
Commercial
2mo ago
From $130K/yr

Principal Scientist, Immunology

Frederick, MD
Research & Development
2mo ago
From $150K/yr
Interview Prep Quick Facts
Portfolio: 1 approved product, 36 clinical trials
Top TAs: Neurology, Infectious Diseases
SEC Filings: 2 available
Open Roles: 22 active jobs
Portfolio Health
Launch1 (100%)
1 total products
Therapeutic Area Focus
Neurology
2 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$10M30%
R&D Spend
$40M(396%)54%
Net Income
-$130M
Cash
$99M
Source: SEC 10-K Filing

Hiring Trend

Actively Hiring
22
Open Roles
+6
Added
-3
Filled/Removed

Based on last 4 crawl cycles